Key facts
- It has raised $154.3M; the latest was Later Stage VC ($84.2M) in Sep 2025.
- Notable investors include HSG (Hong Kong), CICC Capital, Oriental Fortune Capital, Tailong VC, HaiBang Ventures — 23 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 23 names
- ·Watchlist + deal alerts for I-Mab (Hangzhou)
- ·The full record, as it builds
Funding rounds
No funding rounds for I-Mab (Hangzhou) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About I-Mab (Hangzhou)
Manufacturer of macromolecular antibody drugs focused on integrated biopharmaceutical research and production. The company specailises in drug discovery, process development, technology transfer, preclinical and clinical research, enabling delivery of high-efficacy antibody therapies through a unified R&D and manufacturing framework.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2019
- Website
- imab-hz.com/
- Ownership
- Privately Held (backing)
I-Mab (Hangzhou) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in I-Mab (Hangzhou) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on I-Mab (Hangzhou) in its N-PORT filings yet. We sweep new filings monthly.